(Marscha) MS Holleman

All publications (3)

• Article (3)

  • M.S. Holleman, H. van Tinteren, H.J.M. Groen, M.J. Al & C.A. Uyl - de Groot (2019). First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. Oncotargets and Therapy, 12, 1413-1421. doi: 10.2147/ott.S189438
  • M.S. Holleman, M.J. Al, R. Zaim, H.J.M. Groen & C.A. de Uyl-de Groot (2019). Cost-effectiveness analysis of first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. The European Journal Of Health Economics, 21, 153-164. doi: 10.1007/s10198-019-01117-3
  • M.S. Holleman, C.A. de Uyl-de Groot, S. Goodall & N. van der Linden (2019). Determining the comparative value of pharmaceutical risk-sharing policies in non-small cell lung cancer using real-world data. Value in Health, 22, 322-331. doi: 10.1016/j.jval.2018.08.007

Teaching (5)

Present position